

EFFECTIVE DATE: 03/01/2023

POLICY LAST UPDATED: 11/16/2022

OVERVIEW

Percutaneous tibial nerve stimulation (PTNS); also known as posterior tibial nerve stimulation) is an electrical neuromodulation technique used primarily for treating voiding dysfunction.

This policy is applicable to Commercial Products. For Medicare Advantage Plans, please refer to the Related Policies section.

MEDICAL CRITERIA

Commercial Products

PTNS is considered reasonable and necessary when the following criteria are met:

- An evaluation by an appropriate specialist, usually a urologist or urogynecologist, has been performed and the specialist has determined that the patient is a candidate for PTNS; and
- The medical record documents that the member has a) been compliant with and failed a trial of symptom-appropriate behavioral therapy of sufficient length to evaluate potential efficacy, and b) been compliant with and has failed or been unable to tolerate a trial of at least two appropriate medications administered for four (4) to eight (8) weeks; and
- The voiding diary shows continued findings of overactive bladder syndrome (OBS); and
- The beneficiary has documented a willingness to attend in-office treatment sessions, to comply with the behavioral therapies, and to continue to keep voiding diaries including documentation of behavioral therapy compliance; and
- Treatment will consist of an initial course of one 30-minute session per week for 12 weeks.

Treatments for relapse shall only be allowed for those patients who achieve a >50% decrease in OBS symptoms with the initial treatment and then relapse.

PRIOR AUTHORIZATION

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial products and obtained via the online tool for participating providers. See the Related Policies section.

POLICY STATEMENT

Commercial Products

PTNS for overactive bladder syndrome is covered when the medical criteria are met.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable coverage for surgery.

BACKGROUND

Common causes of non-neurogenic voiding dysfunction are pelvic floor neuromuscular changes (eg, from pregnancy, childbirth, surgery), inflammation, medication (eg, diuretics, anticholinergics), obesity, and psychogenic factors. Overactive bladder is a non-neurogenic voiding dysfunction characterized by urinary frequency, urgency, urge incontinence, and nonobstructive retention.

Neurogenic bladder dysfunction is caused by neurologic damage in patients with multiple sclerosis, spinal cord injury, detrusor hyperreflexia, or diabetes with peripheral nerve involvement. The symptoms include overflow incontinence, frequency, urgency, urge incontinence, and retention.

The current indication cleared by the U.S. Food and Drug Administration (FDA) for PTNS is overactive bladder and associated symptoms of urinary frequency, urinary urgency, and urge incontinence.

Altering the function of the posterior tibial nerve with PTNS is believed to improve voiding function and control. The mechanism of action is believed to be retrograde stimulation of the lumbosacral nerves (L4-S3) via the posterior tibial nerve located near the ankle. The lumbosacral nerves control the bladder detrusor and perineal floor.

Administration of PTNS consists of inserting a needle above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation that produces sensory and motor responses as evidenced by a tickling sensation and plantarflexion or fanning of all toes. Noninvasive PTNS has also been delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

PTNS is less invasive than traditional sacral nerve neuromodulation which has been successfully used to treat urinary dysfunction but requires implantation of a permanent device. In sacral root neuromodulation, an implantable pulse generator that delivers controlled electrical impulses is attached to wire leads that connect to the sacral nerves, most commonly the S3 nerve root that modulates the neural pathways controlling bladder function.

For individuals who have non-neurogenic urinary dysfunction including overactive bladder and have failed behavioral and pharmacologic therapy who receive an initial course of PTNS, the evidence includes randomized sham-controlled trials, randomized controlled trials (RCTs) with an active comparator, and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The Sham Effectiveness in Treatment of Overactive Bladder Symptoms (SUMiT) and the Overactive Bladder Innovative Therapy (OrBIT) trials are 2 key industry-sponsored RCTs. Systematic reviews that included these and other published trials have found short-term reductions in voiding dysfunction with PTNS. The largest, highest quality study was the double-blind, sham-controlled SUMiT trial, which reported a statistically significant benefit of PTNS versus sham at 12 weeks. In an additional, small sham-controlled trial, a 50% reduction in urge incontinent episodes was attained in 71% of the PTNS group compared with 0% in the sham group. The nonblinded OrBIT trial found that PTNS was noninferior to medication therapy at 12 weeks. Adverse events were limited to local irritation effects. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Additionally, clinical input was sought to help determine whether the use of maintenance PTNS for individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and respond to an initial course of PTNS would provide a clinically meaningful improvement in the net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 3 physician respondents identified by specialty societies. For individuals with non-neurogenic urinary dysfunction including overactive bladder who have failed behavioral and pharmacologic therapy and respond to an initial course of PTNS, clinical input supports this use provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice.

For individuals who have overactive bladder syndrome that has failed behavioral and pharmacologic therapy who respond to an initial course of PTNS and who receive maintenance PTNS, the evidence includes observational studies and systematic reviews. Relevant outcomes are symptoms, change in disease status,

functional outcomes, quality of life, and treatment-related morbidity. The SUMiT and OrBIT trials each included extension studies that followed individuals who responded to the initial course of PTNS and continued to receive periodic maintenance therapy. There is variability in the interval between and frequency of maintenance treatments, and an optimal maintenance regimen remains unclear. There are up to 36 months of observational data available, reporting that there is a durable effect for some of these patients. While comparative data are not available after the initial 12-week treatment period, the observational data support a clinically meaningful benefit for use in individuals who have already failed behavioral and pharmacologic therapy and who respond to the initial course of PTNS. Percutaneous tibial nerve stimulation may allow such individuals to avoid more invasive interventions. Adverse events appear to be limited to local irritation for both short- and long-term PTNS use. Typical regimens schedule maintenance treatments every 4-6 weeks. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

PTNS has been proposed as a treatment for non-neurogenic and neurogenic bladder syndromes and fecal incontinence.

For individuals who have neurogenic bladder dysfunction who receive PTNS, the evidence includes several RCTs and a systematic review of RCTs and observational data. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Only a few RCTs evaluating tibial nerve stimulation for treating neurogenic bladder have been published to date, and all but 1 performed transcutaneous stimulation rather than PTNS. Studies varied widely in factors such as study populations and comparator interventions. Study findings have not reported that tibial nerve stimulation significantly reduced incontinence symptoms and improved other outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have fecal incontinence who receive PTNS, the evidence includes several RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The available RCTs have not found a clear benefit of PTNS. None of the sham-controlled trials found that active stimulation was superior to sham for achieving a reduction in mean weekly fecal incontinence episodes. The larger sham-controlled randomized trial did find a significantly greater decrease in the absolute number of weekly incontinence episodes in the active treatment group, but the overall trial findings did not suggest the superiority of PTNS over sham treatment. An additional sham-controlled randomized trial did not identify a benefit of PTNS over sham stimulation. A meta-analysis of a single RCT and several observational studies reported that patients receiving sacral nerve stimulation experienced significant benefits compared with patients receiving PTNS. A post hoc analysis of the larger trial suggested a subset of patients with fecal incontinence (those without concomitant obstructive defecation) may benefit from PTNS. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Commercial Products

The following CPT code is covered when criteria are met:

64566 Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

RELATED POLICIES

Prior Authorization via Web-Based Tool for Procedures

Medicare Advantage Plans National and Local Coverage Determinations

PUBLISHED

Provider Update, January 2023

Provider Update, November 2021

Provider Update, October 2020

REFERENCES

1. Centers for Medicare and Medicaid Services, Local Coverage Determination (LCD) for Posterior Tibial Nerve Stimulation for Voiding Dysfunction (L33396), <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33396&ver=10&bc=0>
2. Centers for Medicare and Medicaid Services, Local Coverage Article (LCA) for Billing and Coding: Posterior Tibial Nerve Stimulation for Voiding Dysfunction (A57453), <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=57453&ver=4&bc=0>
3. Cooperberg MR, Stoller ML. Percutaneous neuromodulation. *Urol Clin North Am.* 2005;32(1):71-78.
4. Daneshgari F, Moy ML. Current indications for neuromodulation. *Urol Clin N Am.* 2005;32:37-40.
5. Doggweiler, Ragi. Will posterior tibial nerve stimulation replace sacral nerve root stimulation as the salvage management of drug resistant urinary urge incontinence? Editorial. *The Journal of Urology.* 2010;184:1835-1836.
6. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *Journal of Urology.* 2010;184:2001-2006.
7. Govier FE, Liwiller S, Nitti V, Kreder KJ, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. *Journal of Urology.* 2001;166:1193-1198.
8. Klingler HC, Pycha A, Schmidbauer J, Marberger M. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. *Urology.* 2000;56:766-771.
9. MacDiarmid SA, Peters SM, Shobeiri SA, et al. Long term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *Journal of Urology.* 2010;183:234-240.
10. Nuhoglu B, Fidan V, Ayyildiz A, Ersoy E, Germiyanoglu C. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. *Int Urogynecol J Pelvic Floor Dysfunct.* 2006;17(3):204-207.
11. Peters K, Carrico D, Burks K. Validation of a sham for percutaneous tibial nerve stimulation (PTNS). *Neurology and Urodynamics.* 2009;28:58-61.
12. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmIT trial. *Journal of Urology.* 2010;183:1438-1443.
13. Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *Journal of Urology.* 2009;182:1055-1061.
14. Product Literature: Percutaneous tibial nerve stimulation for the treatment of urinary urgency, urinary frequency and urge incontinence. An overview of the procedure and review of the clinical documentation. Performed with the Urgent® PC Neuromodulation system. Product Information, FDA Documentation, Clinical Summary Report. Uroplasty, Inc.
15. Ruiz BC, Outeirino PXMP, Martinex PC, Duenas EL. Peripheral afferent nerve stimulation for treatment of lower urinary tract irritative symptoms. *European Urology.* 2004;45:65-69.
16. Van Balken MR, Vergunst H, Bemelmans BLH. Prognostic factors for successful percutaneous tibial nerve stimulation. *European Urology.* 2006;49:360-365.
17. Van Balken MR, Vandoninck V, Gisole KWH, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. *Journal of Urology.* 2001;166:914-918.
18. Van der Pal F, van Balken MR, Heesakkers J, Debruyne FMJ, Kiemieney LALM, Bemelmans LH. Correlation between quality of life and voiding variables in patients treated with percutaneous tibial nerve stimulation. *BJU International.* 2006;97:113-118.
19. Van der Pal F, van Balken MR, Heesakkers J, Debruyne FMJ, Bemelmans BLH. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? *BJU International.* 2006;97:547-550.
20. Vandoninck V, van Balken MR, Agro EF, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. *Neurology and Urodynamics.* 2003;22:227-252.

21. Vandoninck V, van Balken MR, Agro EF, et al. Posterior tibial nerve stimulation in the treatment of urge incontinence. *Neurology and Urodynamics*. 2003;22:17-23.
22. Wellpoint Medical Policy – Treatments for Urinary Incontinence and Urinary Retention – SURG.00010 – 02/25/2010
23. Zinkgraf K, O’Leary Quinn A, Ketterhagen D, Kreuziger, B, Stevenson K. Percutaneous tibial nerve stimulation for treatment of overactive bladder and urinary retention in an elderly population. *Urologic Nursing*. 2009;29(1):30-34.
24. Finazzi-Agrò E, Rocchi C, Pachatz C, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modification of the long latency somatosensory evoked potentials. *Neurourol Urodynam*. 2009;28:320-324.
25. Food and Drug Administration (FDA) [website]. Center for Devices and Radiological Health (CDH). Guidance for Industry and FDA Staff – Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence. March 8, 2011. <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070852.htm>. Accessed 8/27/2011.
26. Leong FC, McLennan MT, Barr SA, Steele AC. Posterior tibial nerve stimulation in patients who have failed anticholinergic therapy: efficacy and time to response. *Female Pelvic Medicine & Reconstructive Surgery*. 2011;17(2):74-75.
27. MacDiarmid SA, Staskin D. Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. *Curr Bldr Dysfunction Rep*. 2009;4:29-33.
28. Schreiner L, dos Santos TG, Knorst MR, Gomes da Silva Filho I. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. *International Urogynecology Journal and Pelvic Floor Dysfunction*. 2010;21:1065-1070.
29. Vandoninck V, van Balken MR, Finazzi-Agrò E, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction: urodynamic data. *Neurourol Urodynam*. 2004;23:246-251.
30. Vandoninck V, van Balken MR, Finazzi-Agrò E, Petta F, Micali F, Heesakkers JPFA et al. Posterior tibial nerve stimulation in the treatment of idiopathic nonobstructive voiding dysfunction. *Urology*. 2003;61:567-572.
31. Wooldridge LS. Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency and urge incontinence: results from a community-based clinic. *Urologic Nursing*. 2009;29(3):177-185.
32. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. *Neurourology and Urodynamics*. doi: 10.1002/nau
33. Finazzi AE, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? *Minerva Urol Nefrol*. 2005; Jun;57(2):119-123.
34. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. American Urological Association (AUA) Guideline. Copyright © 2012 American Urological Association Education and Research, Inc.®
35. Karademir K, Baykal K, Sen B, et al. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. *Scand J Urol Nephrol*. 2005;39(3):230-233.
36. MacDiarmid S, Peters KM, Wooldridge L. 12 month percutaneous tibial nerve stimulation treatment interval results: Outcomes from the Orbit trial. Paper presented at: *Neurourology and Urodynamics, 2010; Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010*.
37. Peters KM, Carrico, DJ, MacDiarmid SA, et al. (2012), Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. *Neurourology and Urodynamics*. doi: 10.1002/nau.22266
38. Peters K, Carrico DJ, Perez-Marrero RA, et al. 12 week results from the Sumit trial: Percutaneous tibial nerve stimulation vs validated sham in those exposed to pharmacologic therapy. *Neurourology and Urodynamics*. 2010;29:988-989.
39. Shamliyan T, Wyman J, Kane RL. Nonsurgical treatments for urinary incontinence in adult women: Diagnosis and comparative effectiveness. comparative effectiveness review No. 36. (Prepared by the

University of Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. Rockville, MD. Agency for Healthcare Research and Quality. April 2012.

40. Surwit E, Campbell JD, Karaszewski K. Neuromodulation of the pudendal, hypogastric, and tibial nerves with pelvic floor muscle rehabilitation in the treatment of urinary urge incontinence. *Neuromodulation: Technology at the Neural Interface*. 2009;12(3):175-179.
41. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. *Neurourology and Urodynamics*. 2012;3:1206-1216.
42. Monga AK, Tracey MR. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. *Int Urogynecol J*. 2012;23:993-1005.
43. Hayes, Inc. L31391 Posterior Tibial Nerve Stimulation for Voiding Dysfunction. April 2013.
44. Leong F, McLennan MT, Barr SA, Steele AC. Posterior tibial nerve stimulation in patients who have failed anticholinergic therapy: efficacy and time to response. *Female Pelvic Med Reconstr Surg*. 2012;17(2):74-75.
45. Levin PJ, Wu JM, Kawasaki A, Weidner AC, Amundsen CL. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. *Int Urogynecol J*. 2012;23(11):1591-1597. doi: 10.1007/s00192-012-1712-4. Epub 2012 Mar 13.
46. Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. *Journal of Urology*. 2013;189:210-216.
47. Moosdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. *Neurourol Urodyn*. 2013;32(3):206-214. doi: 10.1002/nau.22296. Epub 2012 Aug 20.
48. Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 30 year results of the STEP study. *Journal of Urology*. 2013;189:2194-2201.
49. Peters KM, Carrico DJ, MacDiarmid SA, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. (2012) *Neurourology and Urodynamics*. 2013;32(1):24029. doi: 10.1002/nau.22266. Epub 2012 Jun 5
50. Yoong W, Shah P, Dadswell R. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. *Int Urogynecol J*. Sept 2012 e-pub ahead of print. doi:10.1007/s00192-1936-3.
51. Blue Cross Blue Shield Association Technology Assessment, "Percutaneous Tibial Nerve Stimulation for the Treatment of Voiding Dysfunction" January 2014.
52. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. American Urological Association (AUA) Guideline. Copyright © 2014 American Urological Association Education and Research, Inc.®

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

